Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifestyle makeover may shield aging brains

NCT ID NCT05256199

Prevention Sponsor: Alzheimercentrum Amsterdam Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a personalized lifestyle program can prevent or slow cognitive decline in older adults (ages 60-79) who have risk factors like high blood pressure or lack of exercise. Over 1,200 participants will either receive intensive coaching on diet, exercise, and brain training, or just general health information online. The goal is to see if the active program improves memory and thinking skills after two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,210 people

The number who actually took part.

Started

Feb 2022

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 60-79 years of age at pre-screening; * Adequate fluency in Dutch to understand the informed consent and complete questionnaires; * Providing informed consent to all study procedures; * Internet access at home; * Presence of ≥3 self-reported risk factors for cognitive decline (must contain at least 2 modifiable risk factors and 1 non-modifiable riskfactor). Exclusion Criteria: * Diagnosis of dementia or mild cognitive impairment at baseline (self-reported); * Significant cognitive impairment assessed using the Modified Telephone Interview for Cognitive Status battery (TICSm score\<23); * Conditions affecting safe and continuous engagement in the intervention (e.g. under treatment for current malignant diseases, major psychiatric disorders (e.g. major depression, psychosis, bipolar disorder), neurological disorders (e.g. Parkinson's disease, multiple sclerosis), symptomatic cardiovascular disease (e.g. stroke, angina pectoris, heart failure, myocardial infarction), re-vascularization within three months, severe loss of vision, hearing or communicative ability, severe mobility impairment, other conditions preventing co-operation) as judged by the local study nurse or consulted physician at the local study site; * Coincident participation in any other intervention trial at time of pre-screening. * Coincident participation of spouse in FINGER-NL trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Risk Reduction Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive decline Life style Risk reduction

Contacts and locations

Locations

  • Alzheimer Center Amsterdam

    Amsterdam, 1671 EA, Netherlands

  • Maastricht University

    Maastricht, Netherlands

  • Radboud University

    Nijmegen, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

  • Wageningen Unversity and Research

    Wageningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.